Objective: To define inflammatory pathways in youth living with HIV infection (YLWH), assessments of biomarkers associated with lymphocyte and macrophage activation, vascular injury, or bone metabolism were performed in YLWH in comparison with healthy controls (HC).
adults. [2] [3] [4] [5] In contrast, few studies have focused on the inflammatory pathways and biomarkers associated with early infection in youth living with HIV infection (YLWH). YLWH, ages 13-24, represent over 25% of newly acquired HIV infections in the United States and are the most rapidly expanding population of infected individuals worldwide. 6 Recent changes in treatment recommendations for the initiation of combination antiretroviral therapy (ART) will lead to treatment of all YLWH independent of CD4 T cell counts or extent of HIV-associated disease. 7, 8 In general, at diagnosis YLWH have higher CD4 T cell counts, fewer comorbidities, and less advanced disease progression than their adult counterparts. 9, 10 YLWH who initiate ART prior to CD4
T cell decline have a high capacity to reconstitute functional T cell immunity, 11 although macrophage and T cell activation, osteopenia, and biomarkers of vascular injury persist, even when viral replication is optimally controlled and CD4 T cell counts are normal. [11] [12] [13] For example, effective ART lowers plasma levels of biomarkers for lymphocyte activation, soluble CD27 (sCD27), and macrophage activation, soluble CD163 (sCD163), compared with untreated individuals, 14, 15 even though biomarker levels among virally suppressed individuals remain elevated compared with HIV-uninfected youth. 11 A comprehensive, integrated assessment of biomarkers associated with lymphocyte, macrophage, vascular, and bone metabolism in YLWH compared with uninfected youth is lacking. The goal of the current study was to examine multiple biomarkers associated with distinct inflammatory pathways altered by HIV infection in YLWH using novel biostatistical modeling to identify inflammatory profiles among YLWH. Understanding the relationship between inflammatory pathways and disease progression in YLWH is critical to designing unique treatment interventions for this population. Identifier NCT00683579). 16 Enrollment was at 22 sites throughout the United States and Puerto Rico; procedures included routine monitoring of clinical HIV disease, neurocognitive assessments, and selfreported substance use. 16 A single blood sample to assess biomarkers was obtained at week 144. Inclusion criteria included age ≥18 and <25 years at enrollment, HIV-infection acquired via behavioral means, and no previous ART. Exclusion criteria included current pregnancy, substance use that would interfere with the ability to complete the study, and significant non-HIV-related cognitive or motor impairment. Participants were stratified at entry based on CD4 T cell counts into 3 study arms; (1) CD4 T cell counts > 350 cells/ L who at entry initiated ART consisting of a protease inhibitor plus 2 nucleotide reverse transcriptase inhibitors; (2) CD4 T cell counts > 350 cells/ L who remained untreated until CD4 counts declined to < 350 cells/ L; and (3) CD4 T cell counts < 350 cells/ L who initiated ART at entry. 16 ufacturer's instructions for 3-or 1-plex panels. To normalize for lower limits of detection, standard curves from each assay were combined to provide one least detectable value. Imputation process and sensitivity analysis were performed to provide a robust data set.
METHODS

Study subjects
Samples below the level of detection were recoded to one significant figure below the lowest detectable value for each biomarker.
Plasma LPS was measured after 1:2 dilution in 0.15 M NaCl and heat inactivated at 65 • C, using the limulus amebocyte assay Chromogenic Endpoint Assay. 14, 18 Because over 40% of HC had levels of IL-2, IL-5, TNF-, or IL-1 below detection in their respective assays, these biomarkers were excluded from further analysis, leaving 19 biomarkers.
Data processing
Raw values for each biomarker were used for correlation analysis.
Natural log-transformed values were used for group comparison on 
Statistical analysis
Chi-square test compared gender and race distribution, whereas
Wilcoxon rank-sum test compared distribution of age, total CD4 count, and CD4 percent between HC and HIV-infected VL + and VL − participants. Linear mixed models, with adjustment for clustering resulting from a shared assay plate, were fit to test the effect of HIV-1 infection, therapy, or virus on each individual biomarker. Multivariate analysis of variance (MANOVA) was conducted to examine the effect of age, gender, ethnicity, HIV infection, ART, and viral levels on bioprofiles consisting of full or refined biomarker panels. Semiparametric Spearman's rank correlation coefficient was used to quantify statistical dependence between pairs of biomarkers in HIV-infected subjects and HC, separately. Heatmaps were produced to visualize the strength of the correlations. PCA biplots were generated to visualize 2-dimensional representation of bioprofiles among groups, whereas the supervised PLS-DA was applied to identify biomarkers that provide the most information in separating of designated groups. Q 2 criterion of leave-one-out cross-validation was used to select the optimal number of PLS-DA components. Identified important factors were ordered using averaged variable importance in projection (VIP) scores for the selected number of components. VIP scores above 1
were considered relevant for group separation. Bonferroni correction was considered to adjust for multiple comparisons based on biomarker categories and control the overall Type I error rate at 0.05.
All statistical analysis results were generated using R 3.1.2 and SAS R 9.4 software.
RESULTS
Demographics of the study cohort
YLWH were 85% male and 67% African American. At entry, average length of infection was 10.75 months based on medical history (Table 1) . At week 144, median age of the 129 YLWH was 24 years median, whereas CD4 T cell count was 651 cells/ L (34%) ( Table 1) Most YLWH, 110 /129 (85%), initiated ART while on study. One subject had missing CD4 and viral load data and was not included in the analysis for Tables 1 and 2 . Of those receiving ART, 79/110 (72%) with viral suppression were classified as VL − , whereas those with detectable plasma virus (28%) were classified as VL + . Among the HC, median CD4
T cell percentage was 46.1%, significantly higher than YLWH, but absolute CD4 T cell counts were similar (723 cells/ L).
HIV infection disrupts normal biomarker levels
There were no significant pairwise differences between HC and YLWH for 10 biomarkers, including osteopontin, lymphocyte markers (sCD25 and IL-10), macrophage (CCL2, IL-1 , IL-6, IL-8, and MMP-2), and cardiovascular (sVCAM-1 and CRP). (Table 2 ) Plasma levels of 9 biomarkers, including lymphocyte (sCD27 and IFN ), monocyte/macrophage (sCD163, sCD14, LPS, TNF , and GM-CSF) and cardiovascular markers (MPO and sICAM-1), were significantly different between HC and YLWH.
To identify the impact of persistent viral replication, biomarkers were evaluated between HC and VL + YLWH ( Bonferroni-corrected significance cut-off to adjust for multiple comparisons: P < 0.002 for lymphocyte and cadiovascular biomarkers, P < 0.00083 for monocyte/macrophage biomarkers, P < 0.0083 for bone-related biomarker. a All values shown are mean (standard deviation). b Indicate statistical significance compared with HC. P values are calculated using mixed model after log transformation.
and osteopontin (bone). When the VL − group was compared with HC, 5 biomarkers (sCD27, sCD163, sCD14, sVCAM, and sICAM) remained different, while sCD25, LPS, TNF , GM-CSF, and MPO were no longer significantly different ( Table 2 ). The potential effect of ART, independent of viral replication, was assessed, but no significant difference for any biomarkers between the groups was detected (Supplemental Table S1 ). No clear confounding variables such as gender, age, ethnicity, or substance use fully provided an explanation for pairwise differences between groups and biomarkers (data not shown).
Impact of HIV infection on biomarker networks
To evaluate the relationships among biomarkers within either the HC or YLWH groups, pairwise Spearman correlations between all 19 biomarkers were performed ( Fig. 1 and Supplemental Table S2 ).
Among HC, significant positive correlations with rho values ranging from 0.485 to 0.822 (P < 0.0002) were identified for 8 lymphocyte and monocyte/macrophage biomarkers (Fig. 1A) . (Fig. 1C ). An unexpected finding was lack of significant correlations between many of the lymphocyte and macrophage activation markers, 
Macrophage and lymphocyte related cytokines contribute to bioprofiles unique to YLWH
PCA was performed to reduce 19 biomarkers into a smaller set of com- biomarkers explained over 30% of the total variance ( Fig. 2A) . Although the HC group was generally distinct from YLWH, considerable overlap between HC and virally suppressed (ART + VL − ) groups was apparent, while VL + groups clustered together independent of treatment.
Similar results occurred when the analysis was limited to the subset of biomarkers of lymphocyte activation (Fig. 2B) . In contrast, the PCA biplot of monocyte/macrophage activation markers showed overlap among all YLWH, independent of treatment or viral load, all distinct from HC. (Fig. 2C ) Based on cardiovascular biomarker-specific PCA biplot, all outcome groups clustered and were indistinguishable from each other (Fig. 2D ). PCA analysis of the 19 biomarkers based on CD4% did not distinguish among groups of YLWH (data not shown).
Overall, clustering the biomarkers into specific inflammatory pathways revealed trends toward differences among the outcome groups.
sCD27, sCD14, and sCD163 are important contributors to separating biomarker bioprofiles in YLWH
To identify biomarkers unique to YLWH a PLS-DA was applied. Components in PLS-DA, designed to separate groups of interest, were applied to visualize the bioprofile based on 19 biomarkers with maximum segregation between HC and the 3 HIV-infected groups. Cross-validation results suggested 2 components were optimal for classification; PLS scores for the first 2 components of the group separation explained 88% of the intergroup variance (Fig. 2E ).
Averaged VIP scores for the first 2 components identified the single biomarkers sCD27, sCD14 and sCD163 as most critical for the discrimination between the outcome group classification, while contributions to the separation by TNF and LPS (Fig. 2F) . Taken together, these results indicate that a subset of markers from lymphocyte and macrophage activation domains contributed to discrimination between HIV + (with or without viral suppression) and HC bioprofiles.
Key biomarker bioprofiles distinguishing YLWH
To determine if bioprofiles containing all 19 biomarkers were significantly altered by HIV infection, therapy, or viral load a MANOVA was conducted using all participants (Table 3) . Information deduced from 19 biomarkers generated unique bioprofiles distinguishing HC from YLWH regardless of ART or VL outcome (P < 0.0001). This bioprofile also identified significant differences within HIV-infected outcome groups based on whether virus was fully suppressed or detectable.
However, the 19-factor bioprofile was unable to distinguish a therapy effect alone, as untreated YLWH were not significantly different from those on ART. Similar results were obtained when the bioprofile was limited to only sCD27, sCD14, and sCD163, the biomarkers iden- provided the most discrimination between YLWH from HC. 
TA B L E 3 Group comparison of bioprofiles utilizing all 19 biomarkers or 3 biomarkers with highest VIP scores
DISCUSSION
HIV perturbs multiple inflammatory pathways through effects on both macrophages and lymphocyte function. As a result biomarkers asso- Previous studies show that control of viral replication by ART has no impact on sCD14 levels, a biomarker of macrophage activation primarily mediated by microbial translocation. 11, 14 This inflammatory pathway remained unchanged even after years of viral suppression and confirms the persistence of macrophage activation due to gastrointestinal microbial translocation and LPS binding to TLR4/CD14. 18 Biomarker measurements have a high degree of variability due to quantitative differences in assay methods, variation in plasma half-life, and overall production levels. 29 Several plasma biomarkers related to key immune pathways were below detectable levels of the assay in a significant proportion of the participants preventing statistical comparisons and therefore not included in the study.
However, correlations between inflammatory biomarkers were identi- [30] [31] [32] [33] [34] [35] [36] In contrast, associations among biomarker networks involved in chronic macrophage activation and vascular injury were seen among YLWH. sCD163 was associated with higher levels of sCD25, a known biomarker of macrophage, activation syndrome, and was also associated with sVCAM and CRP in conditions associated with vascular injury in both HIV and non-HIV associated conditions such as autoimmune disease. 13, 23, 26, [37] [38] [39] [40] While both sCD14
and sCD163 are associated with macrophage activation, the markers represent distinct pathways impacted by HIV; therefore, the lack of associations between these 2 biomarkers is not surprising but indicate complex effects by HIV infection on multiple innate immunity pathways. 41, 42 Complex relationships between HIV-related inflammatory path- The pathways identified in YLWH can be compared with the casecontrolled studies of HIV-infected adults who have developed HIVassociated comorbidities such as myocardial infarction and stoke. 27 Plasma biomarkers similar to both groups include TNF and sCD14, whereas IL-6 is more associated as biomarkers of HIV comorbidities in older adults. 4, 27, 39 The current study identifies similarities and differences among viral outcome groups and is unique in its focus on YLWH who are still healthy and early in disease. YLWH ages 18-24 years are the predominant populations for newly infected youth. 43 The exclusion of younger adolescents under 18 years limits the applicability of the findings to all YLWH. However, examining changes in inflammatory biomarkers over time provides an opportunity to create novel models to assess the development of HIV-associated comorbidities across the life span. 
